GLINT.

GlucoCEST Imaging in Neoplastic Tumours

Developing an innovative radiation-free MR imaging method for cancer assessment

Cancer-detecting MR technology using sugar

GLINT will validate GlucoCEST MRI as an innovative in vivo metabolic imaging technique for earlier, more accurate cancer detection and bring combined examinations of D-glucose and 3-O-methyl-D-glucose to the clinic.

Non-ionizing method for treatment monitoring

GLINT will provide a less invasive MRI method as radiolabelled compounds are not required and make it easier to follow early response to therapy.

Improved clinical decisions

GLINT will benefit the global cancer population by improving the diagnostic accuracy of MRI. More reliable and predictive of disease outcome than the current standard FDG-PET, the GLINT method will lead to improved clinical decisions and outcomes.

Potential for non-cancer diseases

GLINT will open the field of metabolic imaging for a multitude of non-cancer diseases and help develop advanced MRI techniques for other potential applications.

The GLINT consortium is made up of a multidisciplinary team of eight partners from leading research institutions and industry

WWW.GLINT-PROJECT.EU